$BIIB News

BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook

UBS Maintains Buy on Biogen, Raises Price Target to $240

HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251

Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240

Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248

TD Cowen Maintains Buy on Biogen, Raises Price Target to $225

Wedbush Maintains Neutral on Biogen, Raises Price Target to $215

Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?

Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ...

Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised

Biogen Q2 Earnings Call Highlights

Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026